Z

Zenas Biopharma Inc
NASDAQ:ZBIO

Watchlist Manager
Zenas Biopharma Inc
NASDAQ:ZBIO
Watchlist
Price: 19.845 USD 3.9%
Market Cap: 789.6m USD
Have any thoughts about
Zenas Biopharma Inc?
Write Note

Intrinsic Value

ZBIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ZBIO stock under the Base Case scenario is 12.938 USD. Compared to the current market price of 19.845 USD, Zenas Biopharma Inc is Overvalued by 35%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZBIO Intrinsic Value
12.938 USD
Overvaluation 35%
Intrinsic Value
Price
Z
Base Case Scenario

Valuation Backtest
Zenas Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZBIO?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Zenas Biopharma Inc

Provide an overview of the primary business activities
of Zenas Biopharma Inc.

What unique competitive advantages
does Zenas Biopharma Inc hold over its rivals?

What risks and challenges
does Zenas Biopharma Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zenas Biopharma Inc.

Provide P/S
for Zenas Biopharma Inc.

Provide P/E
for Zenas Biopharma Inc.

Provide P/OCF
for Zenas Biopharma Inc.

Provide P/FCFE
for Zenas Biopharma Inc.

Provide P/B
for Zenas Biopharma Inc.

Provide EV/S
for Zenas Biopharma Inc.

Provide EV/GP
for Zenas Biopharma Inc.

Provide EV/EBITDA
for Zenas Biopharma Inc.

Provide EV/EBIT
for Zenas Biopharma Inc.

Provide EV/OCF
for Zenas Biopharma Inc.

Provide EV/FCFF
for Zenas Biopharma Inc.

Provide EV/IC
for Zenas Biopharma Inc.

Show me price targets
for Zenas Biopharma Inc made by professional analysts.

What are the Revenue projections
for Zenas Biopharma Inc?

How accurate were the past Revenue estimates
for Zenas Biopharma Inc?

What are the Net Income projections
for Zenas Biopharma Inc?

How accurate were the past Net Income estimates
for Zenas Biopharma Inc?

What are the EPS projections
for Zenas Biopharma Inc?

How accurate were the past EPS estimates
for Zenas Biopharma Inc?

What are the EBIT projections
for Zenas Biopharma Inc?

How accurate were the past EBIT estimates
for Zenas Biopharma Inc?

Compare the revenue forecasts
for Zenas Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zenas Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zenas Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zenas Biopharma Inc compared to its peers.

Compare the P/E ratios
of Zenas Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zenas Biopharma Inc with its peers.

Analyze the financial leverage
of Zenas Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Zenas Biopharma Inc.

Provide ROE
for Zenas Biopharma Inc.

Provide ROA
for Zenas Biopharma Inc.

Provide ROIC
for Zenas Biopharma Inc.

Provide ROCE
for Zenas Biopharma Inc.

Provide Gross Margin
for Zenas Biopharma Inc.

Provide Operating Margin
for Zenas Biopharma Inc.

Provide Net Margin
for Zenas Biopharma Inc.

Provide FCF Margin
for Zenas Biopharma Inc.

Show all solvency ratios
for Zenas Biopharma Inc.

Provide D/E Ratio
for Zenas Biopharma Inc.

Provide D/A Ratio
for Zenas Biopharma Inc.

Provide Interest Coverage Ratio
for Zenas Biopharma Inc.

Provide Altman Z-Score Ratio
for Zenas Biopharma Inc.

Provide Quick Ratio
for Zenas Biopharma Inc.

Provide Current Ratio
for Zenas Biopharma Inc.

Provide Cash Ratio
for Zenas Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Zenas Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Zenas Biopharma Inc?

What is the current Free Cash Flow
of Zenas Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zenas Biopharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Zenas Biopharma Inc

Balance Sheet Decomposition
Zenas Biopharma Inc

Current Assets 188.6m
Cash & Short-Term Investments 183.9m
Other Current Assets 4.7m
Non-Current Assets 11.4m
PP&E 706k
Other Non-Current Assets 10.6m
Current Liabilities 39.1m
Accounts Payable 8.4m
Accrued Liabilities 29.8m
Other Current Liabilities 939k
Non-Current Liabilities 14k
Other Non-Current Liabilities 14k
Efficiency

Earnings Waterfall
Zenas Biopharma Inc

Revenue
50m USD
Operating Expenses
-106.4m USD
Operating Income
-56.4m USD
Other Expenses
1.7m USD
Net Income
-54.8m USD

Free Cash Flow Analysis
Zenas Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZBIO Profitability Score
Profitability Due Diligence

Zenas Biopharma Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Negative Revenue Growth Forecast
Negative Operating Income
Negative Net Income
33/100
Profitability
Score

Zenas Biopharma Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

ZBIO Solvency Score
Solvency Due Diligence

Zenas Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Zenas Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZBIO Price Targets Summary
Zenas Biopharma Inc

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZBIO is 37.485 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.

Lowest
Price Target
27.27 USD
37% Upside
Average
Price Target
37.485 USD
89% Upside
Highest
Price Target
47.25 USD
138% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZBIO?

Click here to dive deeper.

Dividends

Zenas Biopharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZBIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Zenas Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

789.7m USD

Dividend Yield

0%

Description

Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.

Contact

MASSACHUSETTS
Waltham
1000 Winter St, Suite 1200
+18572712954
zenasbio.com

IPO

2024-09-13

Employees

114

Officers

CEO & Chairman of the Board
Mr. Leon Oliver Moulder Jr., M.B.A.
COO & President
Mr. Joseph L. Farmer
Chief Business Officer & CFO
Ms. Jennifer A. Fox
Head of Research & Development and Chief Medical Officer.
Dr. Tanya Z. Fischer M.D., Ph.D.
Chief Legal Officer
Mr. Jeffrey Held
Chief Human Resources Officer
Ms. Caroline Chevalier
Show More
Chief Commercial Officer
Mr. Orlando Oliveira
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZBIO stock?

The intrinsic value of one ZBIO stock under the Base Case scenario is 12.938 USD.

Is ZBIO stock undervalued or overvalued?

Compared to the current market price of 19.845 USD, Zenas Biopharma Inc is Overvalued by 35%.

Back to Top